U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07211607) titled 'I.V. Selonabant in Healthy Adult Subjects' on Sept. 29.
Brief Summary: This is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous Selonabant in Healthy Adult Subjects Aged 18 to 25 Years
Study Start Date: Sept. 22
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers
Intervention:
DRUG: selonabant
Intravenous infusion of selonabant
DRUG: placebo
Placebo infusion which looks the same as the selonabant infusion
Recruitment Status: RECRUITING
Sponsor: Anebulo Pharmaceuticals
Disclaimer: Curated by HT Syndication....